Dostinex
Dostinex Price range: $ 114,00 through $ 362,00
Back to products
Doxt-SL
Doxt-SL Price range: $ 44,00 through $ 162,00

Doxazosin

Price range: $ 42,00 through $ 332,00

Doxazosin is a versatile alpha-blocker medication primarily used to treat hypertension and benign prostatic hyperplasia. It works by relaxing the blood vessels, which allows blood to flow more easily and helps lower elevated blood pressure levels. For men experiencing an enlarged prostate, this treatment effectively relaxes the muscles of the bladder neck to improve urinary symptoms. Managing blood pressure with this medication can play a vital role in reducing the long-term risk of strokes and heart attacks. This medication provides a reliable approach for those focusing on their cardiovascular wellness and urinary health.

Active substance: Doxazosin
SKU: Doxazosin Categories: , ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Doxazosin belongs to a group of medicines called selective alpha-1 adrenergic receptor antagonists. It is an FDA-approved prescription drug formulated to manage essential hypertension (high blood pressure) and to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). In clinical practice, such as in medical centers in Houston or throughout the United States, doxazosin is dispensed exclusively pursuant to a valid prescription from a licensed healthcare provider in accordance with federal and state regulations.

The clinical utility of doxazosin stems from its targeted action on smooth muscle tissue within the arterial wall and the prostate gland. By selectively inhibiting specific adrenergic signals, the drug reduces peripheral vascular resistance and mitigates urinary outflow obstruction, offering therapeutic benefit for patients diagnosed with cardiovascular or urological conditions.

Parameter Specification
Active Ingredient Doxazosin mesylate
Therapeutic Class Alpha-1 adrenergic blocker (Quinazoline derivative)
Dosage Form Oral tablet (immediate-release), extended-release tablet
Route of Administration Oral
Prescription Status Prescription (Rx) only
Primary Purpose Management of hypertension and benign prostatic hyperplasia (BPH)

Approved Indications and Off-Label Uses

Doxazosin is approved by the U.S. Food and Drug Administration (FDA) for two main clinical indications:

  • Benign Prostatic Hyperplasia (BPH): Doxazosin is indicated to treat both the urinary obstruction and the lower urinary tract symptoms (LUTS) associated with BPH, such as urinary frequency, urgency, weak stream, and nocturnal urination. It may be used as monotherapy or in combination with 5-alpha reductase inhibitors.
  • Hypertension: Doxazosin is indicated for the treatment of high blood pressure. It can be administered as a single agent or in combination with other antihypertensive medications, such as thiazide diuretics, beta-blockers, or calcium channel blockers.

In clinical practice, healthcare providers may occasionally prescribe doxazosin for conditions outside of its FDA-labeled indications. A notable off-label use includes medical expulsive therapy (MET) for distal ureteral stones, where the relaxation of ureteral smooth muscle facilitates the spontaneous passage of urinary calculi. This indication is off-label and has not received formal FDA approval; any such use must be evaluated and managed strictly under specialist clinical supervision.

Mechanism of Action and Pharmacokinetic Profile

Doxazosin selectively inhibits post-junctional alpha-1 adrenergic receptors. In the vascular smooth muscle, this blockade diminishes peripheral vascular resistance, leading to a reduction in systemic arterial blood pressure. In the prostate gland, bladder neck, and prostatic capsule, alpha-1 receptor antagonism relaxes the smooth muscle tone, thereby reducing resistance to urine flow and alleviating dynamic urinary obstruction without impairing bladder contractility.

Pharmacokinetic studies demonstrate that doxazosin mesylate exhibits predictable absorption and elimination characteristics following oral administration:

  • Absorption and Bioavailability: Following oral administration of immediate-release formulations, peak plasma concentrations (Cmax) are reached within approximately 2 to 3 hours. The absolute bioavailability of doxazosin is approximately 65%. Food intake does not clinically alter the total systemic exposure of the immediate-release formulation.
  • Protein Binding and Distribution: Doxazosin exhibits high plasma protein binding, with approximately 98% of the circulating compound bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein. The apparent volume of distribution indicates extensive tissue distribution.
  • Metabolism: Doxazosin undergoes extensive hepatic metabolism via demethylation and hydroxylation pathways, primarily mediated by cytochrome P450 enzymes (including CYP3A4, CYP2D6, and CYP2C19). Several inactive metabolites are formed, along with active metabolites that contribute minimally to overall pharmacological activity.
  • Elimination: The plasma elimination half-life of doxazosin is approximately 22 hours. This prolonged half-life supports once-daily dosing. The primary route of excretion is via the feces (approximately 63% to 65% of the dose, mostly as metabolites), while urinary excretion accounts for approximately 9% of the administered dose.

Dosage and Administration Guidelines

Doxazosin therapy requires individualized dosing tailored to the specific indication and patient response. Treatment must initiate at a low dose to minimize the risk of severe postural hypotension and syncope, a phenomenon commonly referred to as the “first-dose effect.”

For benign prostatic hyperplasia and hypertension, the standard initial dose of immediate-release doxazosin is 1 mg once daily, administered at bedtime. Based on clinical response, standing blood pressure readings, and tolerability, the dosage may be titrated by the prescriber at intervals of 1 to 2 weeks:

  • BPH Dosage Range: Titration may proceed from 1 mg to 2 mg, then to 4 mg, up to a maximum recommended dose of 8 mg once daily.
  • Hypertension Dosage Range: Titration may proceed sequentially to 2 mg, 4 mg, 8 mg, up to a maximum recommended dose of 16 mg once daily.

If treatment is interrupted for several days, re-titration starting from the 1 mg initial dose is generally required to avoid acute postural hypotensive events.

Skipped Dose Instructions: If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Patients should not double the dose to compensate for a missed administration. If several doses are skipped consecutively, the prescribing healthcare provider should be consulted before resuming therapy.

Adverse Reactions and Important Precautions

Clinical trials and post-marketing surveillance have identified several potential adverse reactions associated with doxazosin administration:

  • Central Nervous System: Dizziness, vertigo, somnolence, headache, and fatigue.
  • Cardiovascular System: Orthostatic hypotension, postural dizziness, syncope (particularly during dose initiation or titration), peripheral edema, and palpitations.
  • Respiratory System: Rhinitis, nasal congestion, and dyspnea.
  • Gastrointestinal System: Nausea, abdominal discomfort, and dry mouth.
  • Urogenital System: Rare instances of priapism (painful, prolonged penile erection unassociated with sexual activity). Priapism requires immediate emergency medical intervention to prevent permanent erectile tissue damage.

Intraoperative Floppy Iris Syndrome (IFIS): Patients undergoing cataract or glaucoma surgery who are taking or have previously taken alpha-1 blockers, including doxazosin, are at risk of developing IFIS. Ophthalmologists must be informed of current or prior doxazosin use prior to surgical procedures.

Special Populations: Caution is advised when administering doxazosin to patients with impaired hepatic function, as the drug is extensively metabolized by the liver. Safety and effectiveness in pediatric populations have not been established by the FDA.

Drug Interactions and Daily Management

Doxazosin exhibits significant pharmacological interactions with several drug classes:

  • Phosphodiesterase-5 (PDE-5) Inhibitors: Co-administration of doxazosin with PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) can produce additive blood-pressure-lowering effects, resulting in symptomatic hypotension or syncope. Caution and stabilized alpha-blocker therapy are mandatory prior to initiating PDE-5 inhibitor treatment.
  • Antihypertensive Agents: Concomitant use with other blood-pressure-lowering medications may enhance hypotensive efficacy, requiring dosage adjustments of one or both agents.
  • CYP3A4 Inhibitors: Strong inhibitors of hepatic CYP3A4 enzymes may increase systemic exposure to doxazosin.

Practical Aspects and Signs of Efficacy: Patients starting treatment should be advised to move slowly when transitioning from a lying or sitting position to standing. Signs of therapeutic efficacy in BPH include improved urinary flow rates, reduced sensation of incomplete bladder emptying, and decreased night-time urination frequencies. For hypertension, efficacy is assessed via routine blood pressure monitoring.

Storage and Expiration: Store doxazosin tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Protect the medication from excess moisture and light. Keep out of reach of children and safely discard expired medication.

Frequently Asked Questions

Why is doxazosin typically prescribed to be taken at bedtime during initial treatment?

Administering the initial dose or an increased dose at bedtime minimizes the risk of symptomatic orthostatic hypotension, dizziness, and syncope, which are most prominent within the first hours following initial exposure.

Is doxazosin safe for long-term management of benign prostatic hyperplasia?

Yes, doxazosin is approved for long-term management of BPH. Periodic clinical evaluation by a physician is necessary to assess symptom progression, urinary dynamics, and cardiovascular stability over extended treatment durations.

What should a patient do prior to planned cataract surgery?

Patients must inform their eye surgeon about past or present use of doxazosin. This enables the surgical team to implement specific perioperative protocols to manage potential Intraoperative Floppy Iris Syndrome (IFIS).

Does alcohol consumption interact with doxazosin therapy?

Alcohol exerts additive vasodilatory effects when combined with alpha-1 blockers. Consuming alcohol while taking doxazosin increases the risk of severe dizziness, lightheadedness, and postural hypotension.

Can doxazosin be discontinued abruptly?

Discontinuation should be discussed with the prescribing provider. Abrupt cessation may lead to a recurrence of elevated blood pressure or urinary outflow symptoms. Re-initiating therapy after a lapse usually requires dose re-titration.

In accordance with FDA requirements.

The information presented here is not a substitute for professional medical advice.

Additional information
Dosage

1 mg

,

2 mg

,

4 mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία